Patients with non-GCB DLBCL and PD-L1 expression are approximately 17% less likely to survive after 5 years than those without PD-L1 expression.

Conferences

Novel targeted therapies are currently being used to improve outcomes and quality of life for patients with advanced and difficult-to-treat hematologic malignancies, according to multiple studies presented at the 59th Annual ASH Annual Meeting and Exposition.

The US Food and Drug Administration (FDA) just announced that it will allow marketing of the first agency-authorized test for use with flow cytometry in order to help in the detection of several leukemias and lymphomas.

Read More

News

Patients with non-GCB DLBCL and PD-L1 expression are approximately 17% less likely to survive after 5 years than those without PD-L1 expression.
Two-years of rituximab maintenance therapy can prolong remission in selected elderly patients with CLL in first remission after an abbreviated front-line course of fludarabine, cyclophosphamide and rituximab.
In a recent study, researchers investigated whether everolimus could improve disease-free survival in patients with high-risk diffuse large B-cell lymphoma in complete remission.
For lymphoma patients, increasing physical activity lowers the risk of death from any cause and from lymphoma, according to results of an observational study.

Quiz

According to a recent study, which characteristic can help improve risk stratification for pediatric patients with acute lymphoblastic leukemia?

The FDA recently approved inotuzumab ozogamicin (Besponsa, Pfizer) as an injectable treatment for adults with which type of blood cancer?

Read More

Research in Review

Nurse navigation focused on the patient and family across the care continuum can effectively guide patients with blood cancer to better care and quality of life (QoL), according to a presentation at the 2017 Oncology Nurse Advisor Navigation Summit (June 15-17, 2017; Austin, TX).

-----

Related Content

Read More

Older patients with chronic myelomonocytic leukemia (CMML) who are treated with hypomethylating agents reduce their risk of disease-related mortality by 28%, according to new research published in Cancer (published online June 16, 2017; doi:10.1002/cncr.30814).

-----

Related Content

Read More

A recent study demonstrated high response rates and tolerable safety profiles in pediatric patients with chronic myeloid leukemia (CML) after treatment with a tyrosine kinase inhibitor (TKI).

-----

Related Content

Read More

Response to positron emission tomography (PET) scan after two cycles of standard treatment allows for early treatment adaption for patients with early-stage Hodgkin lymphoma, according to research published in the Journal of Clinical Oncology (June 2017;35[16]:1786-1794).

-----

Related Content

Read More

Slideshow

B-cell malignancies are among the most deadly and difficult-to-treat blood disorders. Our understanding of treatment options, prognostic indicators, and value in B-cell malignancies is constantly evolving. Within the past 6 months, there have been numerous breakthroughs in B-cell malignancy therapies, biomarkers, prognoses, and mutational understandings.

Read More

Subscribe to Leukemia & Lymphoma